Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Scinai Immunotherapeutics Ltd SCNI

Scinai Immunotherapeutics Ltd, formerly known as BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company that is principally focused on developing, manufacturing, and commercializing medical products for the prevention and treatment of autoimmune and infectious diseases but also for other illnesses. The Company’s core focus is to develop NanoAbs for the treatment of various... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >

Current News (NDAQ:SCNI)

Scinai Immunotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement; Continues to Work with the European Investment Bank to Convert Loan to Equity to Regain Compliance with Nasdaq Minimum Shareholders' Equity Requirement

PR Newswire 15 hours ago

Scinai Immunotherapeutics Announces Receipt of a Nasdaq Staff Determination Letter Regarding Shareholders' Equity listing requirements and Hearing to Present a Plan for Regaining Compliance

PR Newswire May 24, 2024

Scinai Publishes FY 2023 Financial Statements, Files Annual Report on Form 20-F and Provides Business Update

PR Newswire May 15, 2024

Scinai Immunotherapeutics Announces Receipt of Nasdaq Delisting Notification and Appeal

PR Newswire May 6, 2024

Scinai to showcase its novel biological local therapeutic for Plaque Psoriasis at Dermatology Drug Development Summit together with Prof. Michael Schön of UMG

PR Newswire April 10, 2024

Scinai Immunotherapeutics' CDMO Unit Selected by Ayana Pharma to Provide Drug Development and cGMP Manufacturing Services

PR Newswire April 8, 2024

Scinai leadership to attend BIO-Europe Spring 2024

PR Newswire March 12, 2024

Scinai to showcase its cGMP biologics CDMO and innovative NanoAb pipeline at MIXiii 2024

PR Newswire February 29, 2024

Scinai Welcomes Liat Halpert as Head of Business Development and Sales

PR Newswire February 13, 2024

Opinion & Analysis (NDAQ:SCNI)

No current opinion is available.

Bullboard Posts (NDAQ:SCNI)

NIH Researchers Unveil AI Tool to Predict Oncology Patients'

NEWS: $SCNI NIH Researchers Unveil AI Tool to Predict Oncology Patients' Response to ImmunotherapyScientists at the National...
whytestocks - 4 hours ago

BVXV....Now if I was a gambling man....

I'd buy this L.O.D.....because theres a gap just over $1.69 that should get filled before the close which is in 15 minutes Me ...no...
Iseneschal - June 5, 2023

BVXV.... Done for the year ?

LMFAO !!!!
Iseneschal - June 5, 2023

BVXV..... Is that a "Green to Red" move..... LoL

Never ceases to amaze me !!!
Iseneschal - June 5, 2023

BVXV....Phew.....call me lucky ; )

Dodged a bullet there But I've re-loaded.....fingers crossed  What a game
Iseneschal - June 5, 2023

BVXV.....sold into that pop

I just take what the market gives I like leaving some for the next guy.....seriously.....this could easily pop Remember my target ; )
Iseneschal - June 5, 2023